THURSDAY, Oct. 18, 2018 — In what researchers are calling a “breakthrough,” two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis. The trials were short-term, finding that the drug combinations improved adult patients’ lung function over four weeks. But experts said they were